(Q33729389)

English

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials (English)

1 reference

Europe PubMed Central

29 July 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S-E Al-Batran

1

1 reference

Europe PubMed Central

29 July 2017

M Güntner

2

1 reference

Europe PubMed Central

29 July 2017

C Pauligk

3

1 reference

Europe PubMed Central

29 July 2017

M Scholz

4

1 reference

Europe PubMed Central

29 July 2017

R Chen

5

1 reference

Europe PubMed Central

29 July 2017

B Beiss

6

1 reference

Europe PubMed Central

29 July 2017

S Stopatschinskaja

7

1 reference

Europe PubMed Central

29 July 2017

W Lerbs

8

1 reference

Europe PubMed Central

29 July 2017

N Harbeck

9

1 reference

Europe PubMed Central

29 July 2017

E Jäger

10

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

26 October 2010

1 reference

Europe PubMed Central

29 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

29 July 2017

103

1 reference

Europe PubMed Central

29 July 2017

10

1 reference

Europe PubMed Central

29 July 2017

1518-1523

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605961

0 references

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Role of anthracyclines in the treatment of early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Third consensus on medical treatment of metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

HER-2 and topoisomerase II as predictors of response to chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Anthracycline cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Pegylated liposomal doxorubicin in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990592

21 June 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605961

21 January 2018

Evaluation of patients with advanced cancer using the Karnofsky performance status

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin-induced cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605961

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33729389&oldid=1672279728"